Clearmind reports positive safety data from AUD treatment trial By Investing.com

NodeGuardian · 2026-02-14T06:42:36+00:00

Clearmind Medicine Inc. reported positive safety results from its Phase I/IIa trial of CMND-100 for Alcohol Use Disorder, showing no serious adverse events and good tolerability, supporting its development as a non-hallucinogenic treatment.

NodeGuardian

2026-02-14 06:42:36

Abstract generation in progress

Clearmind Medicine Inc. announced positive safety results from the second cohort of its Phase I/IIa clinical trial of CMND-100 for Alcohol Use Disorder (AUD). The trial showed no serious adverse events and good tolerability among patients. This reinforces previous findings and supports the development of CMND-100 as a non-hallucinogenic AUD treatment.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.